Corticorelin Market Opportunity in Peritumoral Brain Edema (PTBE) expected to exceed USD 1 billion; Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog LIESTAL, Switzerland--(BUSINESS WIRE)- ...
Curatis’ lead product candidate, C-PTBE-01 (corticorelin), is being developed to treat peritumoral brain edema (PTBE). PTBE occurs in association with many primary and metastatic (secondary) brain ...
The issuer is solely responsible for the content of this announcement. Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain ...
Curatis Holding AG (SIX:CURN, 'Curatis') reports business revenues of CHF 6.9m for 2024, whereby Curatis AG is only included for 8 months. Curatis AG was able to increase sales in the distribution ...
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an ...
* Curatis Holding AG acquired Curatis AG effective on 26 April 2024, and the acquisition is based on the values of the audited opening balance sheet as per 30 April 2024. Therefore, the financial ...
Corticorelin Market Opportunity in Peritumoral Brain Edema (PTBE) expected to exceed USD 1 billion; Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog An epidemiological market study ...
The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Liestal, Switzerland, 23 May 2025: An epidemiological market study commissioned by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results